Addressing the Multifaceted Nature of AAV Immunogenicity

Time: 9:00 am
day: Day One


  • Immunogenicity of AAV is complex and challenging, involving elements of innate, humoral and cellular immunity that can adversely impact patient eligibility, safety, efficacy, durability of treatment, and ability to re-dose
  • Mitigation strategies should account for all aspects of immunogenicity
  • Discussing data on the effects of ImmTOR tolerogenic nanoparticles on innate, CD8 T cell, and antibody responses to AAV and combination strategies to address high dose toxicity